Alterations in the Cerebellar (Phospho)Proteome of a Cyclic Guanosine Monophosphate (cGMP)-dependent Protein Kinase Knockout Mouse*†

Eleonora Corradini‡§, Raghavan Vallur¶,**, Linsey M. Raaijmakers‡§, Susanne Feil¶, Robert Feil¶, Albert J. R. Heck‡§‡‡, and Arjen Scholten‡§‡‡

The cyclic nucleotide cyclic guanosine monophosphate (cGMP) plays an important role in learning and memory, but its signaling mechanisms in the mammalian brain are not fully understood. Using mass-spectrometry-based proteomics, we evaluated how the cerebellum adapts its (phospho)proteome in a knockout mouse model of cGMP-dependent protein kinase type I (cGKI). Our data reveal that a small subset of proteins in the cerebellum (~3% of the quantified proteins) became substantially differentially expressed in the absence of cGKI. More changes were observed at the phosphoproteome level, with hundreds of sites being differentially phosphorylated between wild-type and knockout cerebellum. Most of these phosphorylated sites do not represent known cGKI substrates. An integrative computational network analysis of the data indicated that the differentially expressed proteins and proteins harboring differentially phosphorylated sites largely belong to a tight network in the Purkinje cells of the cerebellum involving important cGMP/cAMP signaling nodes (e.g. PDE5 and PKARIβ) and Ca²⁺ signaling (e.g. SERCA3). In this way, removal of cGKI could be linked to impaired cerebellar long-term depression at Purkinje cell synapses. In addition, we were able to identify a set of novel putative (phospho)proteins to be considered in this network. Overall, our data improve our understanding of cerebellar cGKI signaling and suggest novel players in cGKI-regulated synaptic plasticity. Molecular & Cellular Proteomics 13: 10.1074/mcp.M113.035154, 2004–2016, 2014.

Knockout (KO)† mouse models represent powerful methods for studying the physiological relevance of a protein. However, to elucidate the effects of KO-induced perturbations on the entire system, systems-wide molecular characterization is needed, as, for instance, provided by (phospho)proteomics. Recent technological and methodological advancements now allow the mapping of protein expression, at least in cell cultures, close to completion (1–3). More challenging, proteomics is also increasingly used to attempt systems-wide proteome characterizations in tissue. This has led to semi-quantitative (4–6) and quantitative (7) reasonably comprehensive proteome data on selected tissues, in both humans and animal models. More recently, proteomics has also been applied for the in-depth profiling of perturbations in the proteome occurring in KO models. For instance, de Graaf et al. (8) used an in-depth proteomic approach to identify the proteins changed by DNA-damage-induced premature aging, using a KO mouse model lacking the excision repair complementing group 1 gene. Another recent study used a mouse model lacking apolipoprotein E in order to identify biomarker candidates for coronary artery disease (9).

Adaptation and/or perturbations in the proteome caused by a KO can lead to changes in protein expression, but, at least equally likely, also to rewiring of signaling networks, through changes in post-translational modifications, such as protein phosphorylation. The application of (phospho)proteomics technology on KO or knock-in models is therefore also extremely relevant, albeit even more challenging. Hilger et al. (10) combined proteomics and phosphoproteomics on a cell line in which a phosphatase had been knocked out. To perform such experiments in a more (disease) relevant context, we should invest in functional, tissue-based phosphoproteomics.

1 The abbreviations used are: KO, knockout; cGMP, cyclic guanosine monophosphate; cAMP, cyclic adenosine monophosphate; cGK, cGMP-dependent protein kinase; PKA, cAMP-dependent protein kinase; WT, wild type; PC, Purkinje cell; LTD, long-term depression; SCX, strong cation exchange; Ti³⁺-IMAC, immobilized titanium (IV) ion affinity chromatography; IS, internal standard; FA, formic acid; ACN, acetonitrile; HAP1, Huntingtin associated protein 1; SERCA3, sarcoplasmic/endoplasmic reticulum calcium ATPase 3; PDE, phosphodiesterase; PKC, protein kinase C; Itpr, inositol 1,4,5-trisphosphate receptor.

© 2014 by The American Society for Biochemistry and Molecular Biology, Inc. This paper is available on line at http://www.mcponline.org

From †Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands; §Netherlands Proteomics Centre, Padualaan 8, 3584 CH Utrecht, The Netherlands; ¶Interfacultaires Instituut voor Biochemie, Universiteit Tübingen, D-72074 Tübingen, Germany; **Graduate School for Cellular and Molecular Neuroscience, Universität Tübingen, D-72074 Tübingen, Germany; **German Center for Neurodegenerative diseases (DZNE), D-72076 Tübingen, Germany

Received October 30, 2013, and in revised form, June 13, 2014

Published, MCP Papers in Press, June 19, 2014, DOI 10.1074/mcp.M113.035154

Author contributions: R.F., A.J.H., and A.S. designed research; E.C., R.V., and L.M.R. performed research; E.C. and A.S. analyzed data; E.C., A.J.H., and A.S. wrote the paper; S.F. provided the mouse model.
teomics approaches. A few examples of such approaches have very recently been reported. Lundby et al. (11) globally assessed phosphorylation events downstream of systemic adrenergic stimulation in mouse cardiac tissue. We recently reported on the use of a cardiac delimited CaMKII inhibited knock-in mouse to probe for substrates using a focused kinase-inhibition directed approach (12). Moreover, a mouse model lacking nitric oxide synthase (13), as a system of interest for Alzheimer disease, was recently studied via (phospho)proteomics.

Here we explored how mature state-of-the-art (phospho)proteomics technology could be used to monitor the adaptation at the proteome level of the mouse cerebellum in a mouse line deficient for cGMP-dependent protein kinase type I (cGKI), also known as PKG-I, a kinase that plays an important role in synaptic plasticity, motor learning, and other brain functions (14). The cGMP-dependent protein kinases are serine/threonine kinases that act as key mediators of nitric oxide (NO) signaling, as well as of the natriuretic peptide pathway (15). In mammals, cGKIs are encoded by two different genes: prkg1 coding for cGKI, and prkg2 coding for cGKII (16). The prkg1 gene encodes two cGKI isoforms, cGKIA and cGKIB (17), which differ in their N-terminal leucine zipper and auto-inhibitory domains. cGKI regulates cardiovascular functions such as smooth muscle and cardiac contractility (16); in the nervous system it modulates synaptic plasticity in the hippocampus (18) and cerebellum (19).

In the mammalian brain, more than 250 protein kinases are expressed, but only a few of these kinases are currently known to contribute to learning and memory. In particular, cGKIA is highly expressed in cerebellar Purkinje cells (PCs) (20, 21). Long-term depression (LTD) is an activity-dependent reduction in the efficacy of synaptic transmission and occurs at the PC synapses. Both a pharmacological approach using a few hundred proteins. In particular, we hypothesize that some of the downregulated phosphoproteins, but certainly not all, may be putative substrates of cGKI.

**In Vivo (Phospho)Proteomics in Cerebellum of cGKI-KO Mice**

**EXPERIMENTAL PROCEDURES**

**Mouse Model**—cGKI-KO mice carrying a null mutation of the prkg1 gene, also termed cGKI-L-/L-, mice, were generated as described previously (24). Six-week-old female wild-type (WT) and cGKI-KO mice on a 129/Sv background were sacrificed, and cerebellae were dissected, snap-frozen with liquid nitrogen, and stored at −80 °C until use. Sample Preparation—Frozen cerebella were lysed by sonication in lysis buffer consisting of 10 ml of 8 M urea in 50 mM ammonium bicarbonate, one tablet of protease inhibitors (Complete Mini EDTA-free mixture, Roche Applied Science), and one tablet of phosphatase inhibitor mixture (PhosSTOP, Roche Applied Science).

After centrifugation (20,000 × g for 10 min at 4 °C), the protein concentration of the supernatant was measured using the Bradford assay, and −1 mg of proteins for each condition was subjected to digestion. Protein reduction and alkylation were performed using final concentrations of 2 mM dithiothreitol and 4 mM iodoacetamide, respectively. Proteins were first digested for 4 h at 37 °C with Lys-C (enzyme/substrate ratio = 1:100). The second digestion was performed overnight at 37 °C with trypsin (enzyme/substrate ratio = 1:100) in 2 M urea. The resulting peptides were chemically labeled using stable isotope dimethyl labeling as described elsewhere (25).

**Strong Cation Exchange**—Three biological replicates were performed. One WT littermate was used as an internal standard (IS) in all the biological replicates and was labeled with the “light” (L) label, and the cGKI-KO mice and the other WT littermates were labeled, respectively, with “intermediate” (I) and “heavy” (H) labels. The labeling efficiency was measured for all the samples and was greater than 95%. The three different labeled samples were reconstituted in 10% formic acid (FA) and mixed in a 1:1:1 ratio prior to fractionation using strong cation exchange (SCX) as described previously (26).

Briefly, the SCX was performed using a Zorbax BioSAX-Related Series II column (0.8-mm inner diameter, 50-mm length, 3.5 μm). SCX solvent A consisted of 0.05% FA in 20% acetonitrile (ACN), and solvent B of 0.05% FA, 0.5 mM NaCl in 20% ACN. The SCX gradient was as follows: 0–0.01 min (0% to 2% B); 0.01–8.01 min (2% to 3% B); 8.01–18.01 min (3% to 8% B); 18.01–28 min (8% to 20% B); 28–38 min (20% to 40% B); 38–44 min (40% to 100% B); 44–48 min (100% B); and 48–50 min (100% to 0% B), at a flow rate of ∼40 μl/min. A total of 45 fractions were collected after the injection of ∼300 μg of labeled peptides and dried down in a vacuum centrifuge prior to LC-MS/MS analysis.

**Ti4+-IMAC Enrichment**—After protein digestion, the cGKI-KO mice cerebella were labeled as heavy and the WT littermates were labeled as intermediate. The labeling efficiency was measured, and then the samples were mixed in a 1:1:1 ratio using the same WT light-labeled IS in all three biological replicates. ∼300 μg of the peptide mixtures were subjected to phosphopeptide enrichment using Ti4+-IMAC material as described previously (27). Briefly, the mixtures of labeled samples were dried to completion and reconstituted in 80% ACN, 6% trifluoroacetic acid (TFA) and loaded onto the Ti4+-IMAC columns. After being washed with 50% ACN, 0.5% TFA, 200 mM NaCl and 50% ACN, 0.1% TFA consecutively, the phosphopeptides were eluted first with 10% ammonia and then with 80% ACN, 2% FA and were dried to completion in a vacuum centrifuge.

**Liquid Chromatography and Mass Spectrometry**—(SCX and Ti4+-IMAC)—After reconstitution in 10% FA, 5% dimethyl sulfoxide, the SCX fractions containing doubly charged peptides were analyzed using nanoflow reverse phase liquid chromatography on a Proxeon Easy-nLC 1000 (Thermo Scientific) coupled to a Q-Exactive mass spectrometer (Thermo, San Jose, CA). The SCX fractions containing triply charged peptides were analyzed on an LTQ-Orbitrap Velos or an Orbitrap Elite (Thermo). Depending on the SCX UV trace, 0.5% to 10% of each fraction was injected. Densely populated 2+ and 3+ fractions were subjected to phosphopeptide enrichment using Ti4+-IMAC material as described previously (27). Briefly, the mixtures of labeled samples were dried to completion and reconstituted in 80% ACN, 6% trifluoroacetic acid (TFA) and loaded onto the Ti4+-IMAC columns. After being washed with 50% ACN, 0.5% TFA, 200 mM NaCl and 50% ACN, 0.1% TFA consecutively, the phosphopeptides were eluted first with 10% ammonia and then with 80% ACN, 2% FA and were dried to completion in a vacuum centrifuge.
fractions were injected twice to minimize undersampling of the mass spectrometer.

Peptides were separated at a constant temperature of 40 °C on an in-house-made 50-cm column (75-μm inner diameter) packed with 1.8-μm C18 resin (Zorbax SB-C18, Agilent, Amstelveen, The Netherlands) and connected to an Orbitrap mass spectrometer (Thermo Scientific) through a nanoelectrospray ion source. The injected peptides were first trapped with a double-fritted trapping column (Reprosil C18, 3 μm, 2 cm × 100 μm, Dr Maisch, GmbH, Ammerbuch, Germany) at a pressure of 800 bar with 100% solvent A (0.1% FA in water) before entering chromatographically separated by a linear gradient of buffer B (0.1% FA in ACN) from 7% up to 30% in 150 min at a flow rate of 150 nl/min.

The enriched phosphopeptides were chromatographically separated with 150-min gradient as described previously and analyzed on an LTQ-Orbitrap Elite.

Nanospray was achieved with an in-house pulled and gold-coated fused silica capillary (360-μm outer diameter, 20-μm inner diameter, 10-μm tip inner diameter) and an applied voltage of 1.7 kV. Full-scan MS spectra (from m/z 350 to 1500) were acquired in the Orbitrap with a resolution of 35,000 for the Q-Exactive and 30,000 for the Orbitrap Velos and Elite. Up to 10 most intense ions above the threshold of 500 counts were selected for fragmentation. Higher-energy C-trap dissociation (HCD) fragmentation was performed when using the Q-Exactive in a data-dependent mode, as previously described (27). For fragmentation using the Velos or Elite instrument, a decision tree method was used as described previously (28).

Data Analysis: SCX—For each raw data file recorded by the mass spectrometer, peak lists were generated using Proteome Discoverer (version 1.3, Thermo Scientific, Bremen, Germany) using a standardized workflow. Peak lists, generated in Proteome Discoverer, were searched using Mascot (version 2.3.02, Matrix Science, London, UK) against a Swiss-Prot database (version 2.3.02, taxonomy Mus musculus, 32,402 protein entries) supplemented with frequently observed contaminants. The database search was performed using the following parameters: a mass tolerance of 50 ppm for the precursor masses and ±0.6 Da for collision-induced dissociation (CID)/electron transfer dissociation (ETD) fragment ions and ±0.05 Da for HCD fragments. Enzyme specificity was set to trypsin with two missed cleavages allowed. Carbamidomethylation of cysteines was set as a fixed modification; oxidation of methionine and dimethyl labeling (L, I, H) of cysteines was performed as variable modifications. Percolator was used to filter the peptide-spectrum matches (PSMs) for <1% false discovery rate. Triplex dimethyl labeling was used as the quantification method (29), with a mass precision for 2 ppm for consecutive precursor mass scans. A retention time tolerance of 0.5 min was used to account for the potential retention time shifts due to deuteration. To further filter for high-quality data, we used the following parameters: high-confidence peptide spectrum matches, minimal Mascot score of 20, minimal peptide length of six, and only unique rank 1 peptides. For the identification and quantitation of the proteins, only unique peptides were considered. To estimate whether the proteins were significantly regulated, t test–based statistics were applied only to the proteins quantified in all the biological replicates with at least one quantified unique peptide passing the above-mentioned filtering criteria. Multiple testing correction was applied by using a permutation-based false discovery rate method in Perseus (30) (number of randomizations = 250, false discovery rate = 0.1, s0 = 0.3), and only the proteins with a ratio of cGKI-KO/IS/WT/IS (cGKI-KO/WT) ≥ 1.7-fold were considered regulated.

Data Analysis: Tryptic IMAC—For the phosphopeptide analysis after Tryptic IMAC enrichment, the same parameters as for the SCX analysis were used, and phosphorylation (S, T, Y) was used as a variable modification. Percolator was used to filter the PSMs for <1% false discovery rate. Phosphorylation sites were localized by applying phosphoRS (v2.0) (31). Triplex dimethyl labeling was used as the quantification method, with a mass precision for 2 ppm for consecutive precursor mass scans. A retention time tolerance of 0.5 min was used to account for the effect of deuteration on retention time. To further filter for high-quality data, we used the following parameters: high-confidence peptide spectrum matches, minimal Mascot score of 20, minimal peptide length of six, only unique rank 1 peptide, and search rank 1 peptide.

Only the ratios of the peptides with the same amino acid sequence, the same number of phosphorylation sites, and identical phosphosite localization in the three biological replicates were averaged. Normalization of the protein ratios obtained in the corresponding biological replicate was used. The cGKI-KO/WT ratios were then subjected to a Significance B test. The phosphopeptides that showed an on/off situation in the cGKI-KO or in the WT were manually quantified with an arbitrary value of 100 or 0.01 for extreme up- or down-regulation, which corresponded to the maximum allowed fold change in the Proteome Discoverer settings used. The significantly changed phosphopeptides were subjected to network analysis using STRING (32).

Two different queries were performed for the up- and down-regulated phosphopeptides, with the following parameters for the active prediction methods: experiments, databases and neighborhood, required confidence (score): high. The obtained networks were implemented with the kinases using the network analysis environment Cytoscape v.2.8.2 (33) using the PhosphoSitePlus plugin. The phosphosites that showed a connection with one or more kinases were manually matched against the database repository PhosphoSitePlus (34).

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (http://proteomexchange.org) via the PRIDE partner repository (35) with the dataset identifier PXD000502.

Western Blot Analysis—After separation via SDS-PAGE, the proteins were transferred onto PVDF membrane. Blots were incubated with rabbit anti-cGKI (36) (1:5000), mouse anti-Huntingtin associated protein 1 (HAP1) (Novus Biological, Littleton, CO, 1:5000), rabbit anti-sarcoplasmic/endoplasmic reticulum calcium ATPase 3 (SERCA3) (Thermo Fisher, 1:2000), goat anti-cAMP-dependent protein kinase type II-β regulatory subunit (PKAIIβ) (Santa Cruz, Santa Cruz Bio technology, Heidelberg Germany, 1:500), rabbit anti-cGMP-specific 3’,5’-cyclic phosphodiesterase (PDE5) (Cell Signaling, Danvers, MA, 1:1000), or mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (GeneTex, Irvine, CA, 1:2000). After several washes, the blots were incubated with appropriate horseradish-peroxidase-labeled secondary antibodies and developed with ECL reagent (GE Healthcare). Proteins were quantified using the program ImageQuantTL 1D v. 7.0 (GE Healthcare).

Immunohistochemistry on Paraffin Sections—Cerebella were fixed overnight at 4 °C using 2% formaldehyde and 0.2% glutaraldehyde in PBS. Subsequently the tissues were dehydrated with an ethanol gradient and embedded in paraffin. 10-μm sections were cut, dried overnight, deparaffinized, and rehydrated. Endogenous peroxidase was blocked using peroxidase blocking solution (300 μl of 30% H2O2 and 130 μl of 10% CH3OH/PBS in a final volume of 1 ml of PBS) for 20 min at room temperature. Then antigen retrieval using the heating method was performed, and the sections were incubated overnight at 4 °C with primary antibodies: rabbit anti-cGKI (1:500) (36) or rabbit anti-SERCA3 (Thermo Fisher, 1:100). Then the sections were incubated with biotinylated secondary antibody (1:200) for 1 h followed by ABC complex (Vectastain ABC Kit, Vector Laboratories, Burlingame, CA) for 30 to 40 min at room temperature, and color was developed using diaminobenzidine peroxidase substrate. Sections were mounted with Shandon Immu-Mount (Thermo Fisher Scientific), and images
were obtained under ×20 magnification using an Axioskop (Zeiss, Jena, Germany).

Immunofluorescence Staining of Frozen Sections—Cerebella were perfusion-fixed using 4% paraformaldehyde in PBS. After dissection, the tissues were incubated in the same fixative at 4 °C overnight. The cerebella were washed twice with PBS, passed through a sucrose gradient (10%, 20%, and 30%), and embedded in O.C.T. compound (VWR International GmbH, Amsterdam, The Netherlands). 10-μm sections were cut at −20 °C and dried. Sections were incubated at 4 °C overnight with rabbit anti-PDE5 (1:500) (37). Then sections were incubated with secondary antibody (Alexa 488, goat anti-rabbit, 1:200) for 1 h at room temperature and mounted with Shandon Immun-Mount (Thermo Fisher Scientific). Images were obtained under ×16 magnification using an Axiovert 200 (Zeiss).

RESULTS

Alterations in the Cerebellar Proteome of cGKI-KO Mice—We first performed an in-depth quantitative proteomics screen on the cerebella of cGKI-KO mice and compared these in a biological triplicate experiment with those of their WT littermates of identical genetic background. After dissection, the cerebellar tissues were processed as schematically described in Fig. 1A and in “Experimental Procedures.” One of the WT mice was used as an IS and multiplexed with three biological replicate comparisons (WT versus cGKI-KO). We used triplex dimethyl stable isotope labeling as described previously to enable us to quantitatively profile the proteome in three samples simultaneously (25). After trypsin digestion, the IS was tagged with the light dimethyl label. In all the biological replicates, the cGKI-KO mice were labeled as medium and the WT mice were labeled as heavy. These three peptide mixtures were fractionated using SCX and consecutively analyzed via reverse phase high-resolution LC-MS/MS using an Orbitrap employing methods essentially as described before (28). We identified a total of 6981 cerebellar proteins (supplemental Fig. S1A), of which 6210 (89%) could be quantified (Fig. 1B, supplemental Fig. S1B, supplemental Table S1A). Among these proteins, more than 95% were quantified with more than one unique peptide (supplemental Fig. S1C).

To strengthen the statistics and reliability, we considered only the proteins for which we obtained both an intermediate/light (cGKI-KO/IS) and a heavy/light (WT/IS) ratio in all three replicates (3755) (supplemental Table S1B). To compare the protein expression levels, we applied a t test to the logarithmic ratios of the cGKI-KO and the WT mice using the Perseus software package (30). After the application of multiple testing corrections, only the significantly regulated proteins with a minimum ratio of cGKI-KO/WT of at least 1.7-fold were considered as differential. Out of 3755 proteins robustly quantified, 86 proteins showed up-regulation and 30 proteins were significantly down-regulated (Table I). As expected, the knocked-out cGKI was the top down-regulated protein.

To put these 116 proteins in functional perspective, we manually scrutinized the literature to better understand the role of these regulated proteins in the cerebellum and their putative role in LTD. Notably, we found that many of the regulated proteins were linked to either cGMP or cAMP signaling. This group contained the cyclic nucleotide degrading phosphodiesterases PDE5 (cGKI-KO/WT = 0.5), PDE1B (cGKI-KO/WT = 2.0), and PDE1C (cGKI-KO/WT = 0.5); the cAMP-dependent protein kinase type II-β regulatory subunit PKAIIβ (cGKI-KO/WT = 2.3); and anchoring scaffolds AKAP5 (cGKI-KO/WT = 2.6) and SPHKAP (cGKI-KO/WT = 0.6). In addition, we observed regulation of several neurotransmitter receptors (i.e. GRIN2B, mGlur7, and VgluT2), ion channels/transporters (i.e. SERCA3, CA2D1, and KCNA4), and signal transduction enzymes (i.e. the already mentioned cyclic nucleotide kinases, but also IP3KA, CaMKIV, CaMKV, LYN, and CDK14). In summary, the adaptation to cGKI-KO at the global proteome level is not enormous, as only 3% of the quantified proteins appeared substantially differentially expressed. However, many of the differentially expressed proteins are involved in cyclic nucleotide signaling and/or play a role in synaptic transmission.

Validation of the Proteomics Results by Western Blot Analysis and Immunostaining of Tissue Sections—We decided to verify some of these results via Western blot analysis, when good antibodies were available (Fig. 2A). Three cerebellar tissues for each condition (i.e. KO versus WT) were analyzed, and the protein levels were quantified from the blots (Fig. 2B). These data confirmed the absence of cGKI in cGKI-KO cerebellum and indicated reduced expression of cGMP-specific PDE5 and the calcium pump SERCA3 in cGKI-deficient cerebellum, whereas PKAIIβ and the HAP1 showed increased expression in the KO cerebellum. All these results are consistent with our proteomics results. However, with MS-based proteomics and Western blot analysis it is hardly possible to say whether the down-regulation of a protein is related to a global change or to an event localized to a particular cell type or region within the cerebellum. Therefore, we next performed immunohistochemistry and immunofluorescence staining of cerebellar sections for cGKI, SERCA3, and PDE5 (Fig. 3). These images clearly indicate that cGKI, SERCA3, and PDE5 were co-expressed in the PCs of WT mice, whereas SERCA3 and PDE5 expression levels were diminished in the cGKI-KO PCs. Thus, the Western blot results, combined with the immunostaining of cerebellar sections, confirmed the data obtained from our MS-based proteomics approach for these selected proteins. These findings also provide confidence in the remainder of reported differentially expressed proteins.

Alterations in the Cerebellar Phosphoproteome of cGKI-KO Mice—Because cGKI is a protein kinase, we next globally profiled altered phosphorylation patterns as a consequence of the proteome rewiring induced by the cGKI deletion. cGKI, like its closest relative PKA, targets serine or threonine phosphorylation sites in its substrates within a basic consensus motif [R/K2–3][S/T] (38). Therefore, we used an adapted Ti4⁺-IMAC-based phosphopeptide enrichment strategy.
shown to be suited for basic kinase motifs (27). For the phosphopeptide enrichment, the same cerebella were used as for the proteome analysis (Fig. 1A). A total of 3690 unique phosphopeptides were identified after we ran the enriched phosphopeptide fractions, of which 3271 could be quantified. 2859 of these quantified phosphopeptides were identified with reasonably definite site localization (phosphoRS $\geq$ 75%) (31) (supplemental Table S2A). Among the localized phosphopeptides, 1696 could be quantified in at least two out of three replicates, whereas 1163 were quantified in just one replicate (supplemental Figs. S2A and S2B). The average of the quantified phosphopeptides (cGKI-KO/WT) from the three biological replicates was subjected to Significance B using the Perseus package in order to define the cutoff for significant regulation. Because the animal model that we used lacks cGKI, we had to consider that several phosphorylation sites could show an on/off regulation. We manually scrutinized the MS spectra of the peptides that showed intensity in only one of the two conditions before giving them an arbitrary value of 100 or 0.01, corresponding to the maximum allowed fold-
| Accession | Gene name | Description | cGKI-KO/WT | S.D. | Number of unique peptides |
|-----------|-----------|-------------|------------|------|--------------------------|
| Q60590    | Orm1      | α-1-acid glycoprotein 1 | 23.45      | 1.46 | 5                        |
| Q91X72    | Hpx       | Hemopexin    | 9.27       | 2.46 | 22                       |
| Q8K0E8    | Fgb       | Fibrinogen β chain | 6.21       | 0.90 | 22                       |
| Q8VCM7    | Fgg       | Fibrinogen γ chain | 5.75       | 1.57 | 20                       |
| Q8CGV2    | Tph2      | Tryptophan 5-hydroxylase 2 | 6.08 | 3.81 | 11                      |
| Q3UHL1    | Camkv     | CaM kinase-like vesicle-associated protein | 4.67 | 1.00 | 11                      |
| P06909    | Ctf       | Complement factor H | 4.24       | 1.08 | 18                       |
| Q5DTY9    | Kctd16    | BTB/POZ domain-containing protein KCTD16 | 4.54 | 1.30 | 5                        |
| Q9R111    | Gda       | Guanine deaminase | 3.46 | 0.71 | 10                       |
| Q35668    | Hap1      | Huntingtin-associated protein 1 | 3.52 | 0.20 | 7                        |
| O08677    | Kng1      | Kinogen-1 | 3.50       | 0.75 | 13                       |
| Q9OU39    | Rasgrp2   | RAS guanyl-releasing protein 2 | 3.46 | 0.85 | 6                        |
| P01029    | C4b       | Complement C4-B | 3.16       | 1.11 | 8                        |
| Q8K3E5    | Ahi1      | Jouberin | 3.05       | 0.43 | 25                       |
| P97467    | Pam       | Peptidyl-glycine α-amidating monooxygenase | 3.15 | 0.91 | 12                       |
| P50153    | Gng4      | Guanine nucleotide-binding protein G(II)/(G(S)/G(O)) subunit γ-4 | 3.09 | 0.84 | 1                        |
| P20918    | Plg       | Plasminogen | 3.04       | 0.93 | 15                       |
| Q61704    | Itih3     | Inter-α-trypsin inhibitor heavy chain H3 | 2.90 | 0.56 | 11                       |
| Q61147    | CERU      | Ceruloplasmin | 3.00       | 0.87 | 22                       |
| Q91ZP9    | Necab2    | N-terminal EF-hand calcium-binding protein 2 | 3.19 | 1.17 | 5                        |
| Q91XV3    | Basp1     | Brain acid soluble protein 1 | 3.02 | 0.67 | 14                       |
| P11276    | Fn1       | Fibronectin | 2.79       | 0.65 | 30                       |
| P01027    | C3        | Complement C3 | 2.92       | 0.99 | 54                       |
| Q92111    | TRFE      | Serotransferrin | 2.84       | 0.81 | 38                       |
| Q9DB26    | Phyhd1    | Phytanoyl-CoA dioxygenase domain-containing protein 1 | 2.84 | 0.81 | 2                        |
| Q81WP6    | Serpina3n | Serine protease inhibitor A3N | 2.85 | 0.65 | 3                        |
| Q8B8H2    | Rab9b     | Ras-related protein Rab-9B | 2.91 | 1.21 | 4                        |
| Q8CHT1    | Ngef      | Ephexin-1 | 2.65       | 0.59 | 3                        |
| Q61423    | Kcnq4     | Potassium voltage-gated channel subfamily A member 4 | 2.71 | 0.89 | 1                        |
| Q35517    | Scg2      | Secretogranin-2 | 2.73 | 0.48 | 19                       |
| Q35526    | Stx1a     | Syntaxin-1A | 2.62       | 0.44 | 11                       |
| Q9C2S1    | Alch1b1   | Aldehyde dehydrogenase X, mitochondrial | 2.64 | 0.42 | 7                        |
| D3YVF0    | Akap5     | A-kinase anchor protein 5 | 2.52 | 0.42 | 7                        |
| Q60673    | Ptpn      | Receptor-type tyrosine-protein phosphatase-like N | 2.75 | 0.83 | 6                        |
| Q9WTR5    | Cdh1      | Cadherin-13 | 2.54 | 0.52 | 9                        |
| Q9WUC3    | Ly6h      | Lympocyte antigen 6H | 2.52 | 0.06 | 4                        |
| Q01097    | Grin2b    | Glutamate [NMDA] receptor subunit ε-2 | 2.41 | 0.50 | 5                        |
| Q9QX07    | Pcs1n     | ProSAAS | 2.59       | 0.53 | 9                        |
| Q68ED2    | Grm7      | Metabotropic glutamate receptor 7 | 2.37 | 1.01 | 4                        |
| P06728    | Apo4      | Apolipoprotein A-IV | 2.37 | 0.87 | 14                       |
| Q3TVW96   | Uap111    | UDP-N-acetylhexosamine pyrophosphorylase-like protein 1 | 2.45 | 0.87 | 8                        |
| P16460    | Ass1      | Argininosuccinate synthase | 2.32 | 0.18 | 8                        |
| P31324    | Prkar2b   | cAMP-dependent protein kinase type II-β regulatory subunit | 2.27 | 0.32 | 13                       |
| Q68FM6    | Elfn2     | Protein phosphatase 1 regulatory subunit 29 | 2.25 | 0.26 | 5                        |
| P19221    | THR8      | Prothrombin | 2.34 | 0.88 | 7                        |
| O54901    | Cd200     | OX-2 membrane glycoprotein | 2.32 | 0.50 | 3                        |
| Q61838    | A2m       | α-2-macroglobulin | 2.19 | 0.62 | 39                       |
| P48320    | Gad2      | Glutamate decarboxylase 2 | 2.20 | 0.37 | 14                       |
| Q921X9    | Pdia5     | Protein disulfide-isomerase A5 | 2.32 | 0.96 | 3                        |
| P08560    | Ptpn2     | Receptor-type tyrosine-protein phosphatase N2 | 2.09 | 0.27 | 16                       |
| P29699    | Ahsg      | α-2-HS-glycoprotein | 2.31 | 1.23 | 4                        |
| Q61247    | Serpin2f  | α-2-antiplasmin | 2.06 | 0.68 | 5                        |
| Q01065    | Pde1b     | Calcium/calmodulin-dependent 3’,5’-cyclic nucleotide phosphodiesterase 1B | 2.09 | 0.58 | 12                       |
| Q8BBL2    | Cpe4      | Copine-4 | 2.08       | 0.53 | 5                        |
| P31650    | Slc6a11   | Sodium- and chloride-dependent GABA transporter 3 | 1.97 | 0.28 | 11                       |
| Q60771    | Cldn11    | Claudin-11 | 2.04 | 0.66 | 3                        |
| Q8R5A6    | Tbc1d22a  | TBC1 domain family member 22A | 2.01 | 0.67 | 7                        |
| Q62188    | Dpys3     | Dihydropyrimidinase-related protein 3 | 1.90 | 0.08 | 17                       |
| P49025    | Cit       | Citron Rho-interacting kinase | 1.94 | 0.45 | 15                       |
| Accession | Gene name | Description | cGKI-KO/WT | S.D. | Number of unique peptides |
|-----------|-----------|-------------|------------|------|--------------------------|
| O54990    | Prom1     | Prominin-1  | 1.91       | 0.46 | 4                        |
| Q2M3X8    | Phactr1    | Phosphatase and actin regulator 1 | 1.85       | 0.41 | 5                        |
| Q9R226    | Khdrbs3    | KH domain-containing, RNA-binding, signal transduction-associated protein 3 | 1.98       | 0.79 | 3                        |
| O35495    | Cdk14     | Cyclin-dependent kinase 14 | 1.96       | 0.63 | 2                        |
| P84075    | Hpc1a      | Neuron-specific calcium-binding protein hippocalcin | 1.86       | 0.49 | 5                        |
| Q0R5M8    | Cadin1     | Cell adhesion molecule 1 | 1.83       | 0.19 | 7                        |
| P70392    | Rasa1f2    | Ras-specific guanine nucleotide-releasing factor 2 | 1.90       | 0.56 | 7                        |
| Q5XG69    | Fam169a    | Protein FAM169A | 1.80       | 0.13 | 9                        |
| P70699    | Gaa        | Lysosomal α-glucosidase | 1.79       | 0.37 | 14                       |
| Q61553    | Fscn1      | Fascin       | 1.75       | 0.12 | 15                       |
| P07356    | Anxa2      | Annexin A2   | 1.78       | 0.21 | 15                       |
| Q80T74    | Kiaa1045   | Protein KIAA1045 | 1.77       | 0.39 | 13                       |
| Q89026    | Robo1      | Roundabout homolog 1 | 1.76       | 0.13 | 5                        |
| O08532    | Cacna2d1   | Voltage-dependent calcium channel subunit α2-δ-1 | 1.80       | 0.42 | 21                       |
| Q5RJG7    | Ispd       | 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase-like protein | 1.73       | 0.03 | 4                        |
| O35633    | Slc32a1    | Vesicular inhibitory amino acid transporter | 1.73       | 0.16 | 10                       |
| Q8BLE7    | Slc17a6    | Vesicular glutamate transporter 2 | 1.73       | 0.37 | 7                        |
| Q9EQ6    | Dpsi5      | Dihydropyrimidinase-related protein 5 | 1.73       | 0.11 | 26                       |
| A2ALU4    | Shroom2    | Protein Shroom2 | 1.73       | 0.18 | 15                       |
| O55091    | Impact1    | Protein IMPACT | 1.82       | 0.54 | 13                       |
| Q61599    | Arhgdibd   | Rho GDP-dissociation inhibitor 2 | 1.74       | 0.35 | 6                        |
| P36552    | Cpox       | Coproporphyrinogen-III oxidase, mitochondrial | 1.70       | 0.22 | 8                        |
| Q3UG6     | Tbc1d24    | TBC1 domain family member 24 | 1.70       | 0.02 | 9                        |
| Q66L44    | Dos        | Protein Dos  | 1.69       | 0.10 | 3                        |
| Q22J6     | Tspan2     | Tetraspanin-2 | 1.69       | 0.14 | 3                        |
| Q8BR0    | Palm2      | Paralemmin-2  | 1.69       | 0.13 | 9                        |
| Q9C980    | Cygb       | Cytooglobin  | 1.68       | 0.19 | 10                       |
| Q8BYJ6    | Tbc1d4     | TBC1 domain family member 4 | 0.63       | 0.05 | 16                       |
| Q9JPN6    | Homer3     | Homer protein homolog 3 | 0.61       | 0.11 | 21                       |
| Q69X8     | Abilim3    | Actin-binding LIM protein 3 | 0.60       | 0.04 | 12                       |
| Q8BYR5    | Cadps2     | Calcium-dependent secretion activator 2 | 0.60       | 0.08 | 34                       |
| P08414    | Camk4      | Calcium/calmodulin-dependent protein kinase type IV | 0.61       | 0.09 | 21                       |
| Q8R071    | Itpka      | Inositol-trisphosphate 3-kinase A | 0.58       | 0.07 | 20                       |
| Q6NSW3    | Spkaph     | A-kinase anchor protein SPHKAP | 0.60       | 0.09 | 26                       |
| Q91ZH7    | Abhd3      | Abhydrolase domain-containing protein 3 | 0.58       | 0.10 | 6                        |
| Q9QUR8    | Sema7a     | Semaphorin-7A | 0.58       | 0.07 | 12                       |
| Q0VEJ0    | Cep76      | Centrosomal protein of 76 kDa | 0.59       | 0.13 | 19                       |
| Q6JZ2     | Tuba8      | Tubulin α-8 chain | 0.57       | 0.07 | 7                        |
| P25911    | Lyn        | Tyrosine-protein kinase Lyn | 0.56       | 0.11 | 7                        |
| Q3UH99    | Shisa6     | Protein shisa-6 homolog | 0.56       | 0.11 | 11                       |
| P18653    | Rps6ka1    | Ribosomal protein S6 kinase α | 0.58       | 0.12 | 17                       |
| Q6WQJ1    | Dagla      | Sn1-specific diacylglycerol lipase α | 0.54       | 0.10 | 14                       |
| Q64338    | Pde1c      | Calcium/calmodulin-dependent 3,5'-cyclic nucleotide phosphodiesterase 1C | 0.53       | 0.10 | 5                        |
| Q5F268    | Fat2       | Protocadherin Fat 2 | 0.56       | 0.19 | 37                       |
| Q8QZT2    | CA096      | Uncharacterized protein C1orf96 homolog | 0.53       | 0.11 | 7                        |
| Q80YX1    | Tnc        | Tenascin     | 0.50       | 0.03 | 45                       |
| P55088    | Aqp4       | Aquaporin-4  | 0.51       | 0.25 | 2                        |
| Q64518    | Atp2a3     | Sarco(endo)plasmic reticulum calcium ATPase 3 | 0.52       | 0.20 | 23                       |
| Q8CG03    | Pde5a      | cGMP-specific 3',5'-cyclic phosphodiesterase | 0.54       | 0.16 | 9                        |
| Q9ERY9    | ORF11      | Probable ergosterol biosynthetic protein 28 | 0.53       | 0.20 | 3                        |
| Q9EOK7    | Icmt       | Protein-S-isoprenylcysteine O-methyltransferase | 0.54       | 0.24 | 3                        |
| Q9ERQ8    | Ca7        | Carbonic anhydrase 7 | 0.49       | 0.11 | 4                        |
| Q64444    | Ca4        | Carbonic anhydrase 4 | 0.52       | 0.19 | 8                        |
| P06537    | Nr3c1      | Glucocorticoid receptor | 0.49       | 0.21 | 6                        |
| P68433    | Hist1h3a   | Histone H3.1 | 0.40       | 0.03 | 5                        |
| P62806    | Hist1h4a   | Histone H4  | 0.35       | 0.01 | 9                        |
| POC605    | Prkg1      | cGMP-dependent protein kinase 1 | 0.01       | 0.00 | 11                       |

**In Vivo (Phospho)Proteomics in Cerebellum of cGKI-KO Mice**
change in the software settings. Using these parameters, we determined that a total of 345 and 113 phosphopeptides, originating from 296 phosphoproteins, could be considered up- or down-regulated, respectively (Fig. 1C).

Global evaluation of the quantitative data showed more changes at the phosphopeptide level than at the protein level; nevertheless, when the phosphopeptides were compared with the peptides used for the protein quantitation, overall they showed a similar and very tight distribution (Fig. 1D).

To visualize how the signaling network in the cerebellum adapted to the cGKI-KO, we evaluated all 296 phosphoproteins against protein and interactome databases such as STRING (32). The proteins showing increased phosphorylation were found to be enriched in Ca2+/H1001 transporters and receptors (i.e. GRID2, CCG7, and SLC32A1), enzyme modulators (i.e. PP14A and MYPT1), G-protein modulators (i.e. SRGAP3 and RIMS1), and cytoskeletal proteins (i.e. CTNNA2, NCAM, and VCL). For proteins showing decreased phosphorylation in the cGKI-KO cerebellum, we identified various proteins such as kinases (i.e. GSK3/3), enzyme modulators (i.e. AMPKb1), and structural proteins (i.e. NEFH and NEM). To further complete the picture of the changes observed in the phosphopeptides that did not show any connection in the networks, we implemented the networks with the possible upstream kinases, identified in our proteomics dataset, and assigned, when possible, the right putative kinases to each regulated phosphosite.

The up-regulated network (Fig. 4A) clearly showed a set of phosphosites that were not directly linked to the KO kinase cGKI but which are thought to be phosphorylated by different kinases, such as PKA, casein kinase 2, and CaMKII. Notably, we identified one of the sites that mediates protein kinase C β (PKCβ) activity (Thr-642) as up-regulated in the cGKI-KO mice. PKCβ activity is regulated through three distinct phosphorylation events that occur at Thr500, at Thr-642 through autophosphorylation, and at the carboxy-terminal site at Ser-660 (39). The up-regulation of the phosphorylated site in the cGKI-KO mice could imply increased activity of PKCβ in the absence of cGKI, potentially to compensate for its lack.

Interestingly, several proteins involved in the regulation of cell survival showed regulated phosphorylations on specific sites reported to be critical for apoptosis. For example, the up-regulation of the phosphorylated Ser-1040 of MAP3K5 suppresses its pro-apoptotic function (40). On the other side, the down-regulation of the phosphorylation at Ser-116 of PEA-15, a downstream effector of PKC, AKT, and CaMKII (Fig. 4B), blocks ERK’s translocation to the nuclei and therefore cell proliferation (41). Also, GSK3β showed a down-regulation of phosphorylation at Ser-389. Thornton et al. (42) showed that phosphorylation of GSK3β by p38 MAPK on
Ser-389 deactivates the kinase in brain, and that it is potentially linked to cell survival.

We hypothesized that we could potentially observe cGKI substrates as being “completely” down-regulated in the cGKI-KO mice. Therefore, we screened within the down-regulated phosphopeptides for peptides harboring a cGKI-linked basic consensus motif. We observed only two, one on the serine/threonine-protein kinase BRSK2, and the other on Gabra6, both of which are involved in neural polarization. The phosphorylated sequences in these two proteins showed an elevated amount of lysine/arginine residues N-terminal to the phosphorylation site, implying that they might be cGKI substrates. Moreover, multiple alignments of both BRSK2 and Gabra6 from different species show that the putative cGKI phosphorylation sites, as well as the preceding basic residues, are well conserved, implying a possible functional role of the two proteins when phosphorylated (Fig. 4C).

**Combined Proteome and Phosphoproteome Data Provide a Link to LTD**—In a recent review, Collingridge et al. (43) proposed an overview of the intricate protein signaling networks involved in the regulation of LTD, in both hippocampus and cerebellum. Using the knowledge retained from the BioGRID and STRING protein–protein interaction databases (44), we observed that we could clearly put our data in the context of LTD. We were able to identify several connections between observed regulated proteins and phosphoproteins involved in cGMP–cGKI signaling and playing a role in cerebellar plasticity (Fig. 5A). We identified, for instance, in our cGKI-KO (phospho)proteome dataset a highly interconnected network among cGKI, inositol 1,4,5-trisphosphate receptor type 1 (ltp1), Huntingtin, HAP1, and its direct interactor Jouberin (AHI1). HAP1 was recently found to form a complex with Huntingtin and ltp1 to regulate the concentration of cytoplasmic Ca^{2+} (45). Furthermore, ltp1 might be a substrate of cGKI, and activation of cGKI regulates cytoplasmic Ca^{2+} through the ltp1-associated cGMP kinase substrate (IRAG) in smooth muscle (46). This could imply that the Ca^{2+} regulation operates through a similar mechanism in cerebellum. Based on these findings we could link our data clearly to the network described as highly involved in LTD (Fig. 5B).

**DISCUSSION**

In past years many studies have been carried out at the molecular biology and physiological levels in an attempt to understand the exact role of cGMP and cGKI in PCs for the regulation of LTD and cerebellar learning.

In this study we started to add much more molecular detail to this interesting field by investigating the changes that occur at the proteome and phosphoproteome levels of the cerebellum in a cGKI-deficient mouse model. Using this approach we identified a specific subset of proteins that were significantly changed in expression in cGKI-KO relative to WT littermates. Within the down-regulated proteins, PDE5 drew our attention, because it plays an important role in the cGMP pathway. The down-regulation of PDE5 in PCs may be explained as a compensatory mechanism for the lack of cGKI action. Attempting to increase the levels of cGMP is a logical response, and the down-regulation of the cGMP-degrading enzyme PDE5 (Fig. 3) (15) is a logical way to achieve this. In line with this observation, several studies revealed that tissues lacking
**Fig. 4. Interaction network of cGKI-KO affected phosphoproteins.** Interaction network for the observed differential phosphorylated proteins. A, phosphosites that were higher in the cGKI-KO mice are given in red, and B, those lower are in green. Evidence of protein–protein interactions (blue lines) was retrieved from the STRING database. The networks were implemented with kinases (yellow diamonds) using the PhosphoSitePlus plugin in Cytoscape. Each phosphorylation was manually checked in the PhosphoSitePlus database and connected with its (known) kinase (arrows). C, alignment of the putative cGKI phosphorylation sites for BRSK2 and Gabra6 in different species implicates a putative role of their phosphorylation in cerebellum.
cGKI show an elevated concentration of cGMP (47, 48). The absence of cGKI and an increase of the cGMP level could lead to the activation of other kinases, such as PKA (47) or PKC (49). PKCII/H925L, indeed, in our dataset, showed high regulation at the phosphorylation level of the activation loop site (Fig. 4B).

Moreover, other proteins that could be involved in LTD in the cerebellum show increased protein expression in the absence of cGKI, such as the protein phosphatase 1 regulatory subunit (PPP1R29). PPP1R29 functions to inhibit the activity of protein phosphatases 1 and 2A. Together with PPP1R29, a protein termed G-substrate also blocks the activity of PP1 after it has been phosphorylated by cGKI (50).

Although we were not able to identify the activation phosphosites of G-substrate at Thr72 and Thr123, we observed that the expression of G-substrate in our biological replicates did show a decreasing trend in the cGKI-KO cerebella (cGKI-KO/WT = 0.58, supplemental Table S1).

This fact could explain the greater amount of the phosphatase regulatory subunit; in fact, in accordance with the general accepted view, the inhibition of PP1 enhances the phosphorylation of the AMPA receptor and its subsequent internalization, with induction of LTD. In view of these results, it is tempting to hypothesize that, in the absence of an adequate level of G-substrate, PPP1R29 is highly expressed, to ensure...
the occurrence of at least a low level of LTD in the cGKI-KO cerebellum.

Ca$^{2+}$ regulation is fundamental in the nervous system, and we were able to quantify significant changes at the protein level of the Ca$^{2+}$ pump SERCA3 (Fig. 3) and of HAP1, which regulates the cytosolic Ca$^{2+}$ concentration in a complex with Itpr1 and Huntingtin (Fig. 2). The altered expression of Ca$^{2+}$ signaling proteins in cGKI-KO cerebellum is in line with the known function of cGKI in the regulation of the intracellular Ca$^{2+}$ level in cardiovascular cells (46). These results warrant a more detailed analysis of potential cross-talk between cGKI and Ca$^{2+}$ signaling in cerebellar PCs.

The combination of proteomics and immunostaining of brain sections gave more information on the localization of the proteins in the cerebellum. It is in fact necessary to understand whether the proteins that change in expression are expressed in PCs and/or in other areas of the cerebellum.

We hypothesize that many of the peptides that showed regulation might be phosphorylated by other kinases that are more active in cGKI-KO or that are direct substrates of cGKI. Furthermore, we were able to identify two potential cGKI phosphorylation substrates (BRKS2 and Gabra6) that showed a down-regulated ratio in the cGKI-KO mice (Fig. 4C).

Overall, we were able to identify significant changes of the cerebellar (phospho)proteome upon genetic ablation of cGKI. As a first validation, we found perturbations on proteins that are involved in synaptic plasticity, such as ion transporters, signal transduction enzymes, and neurotransmitter receptors. The combination of the protein–protein interaction results with the current literature on cerebellar LTD allowed us to highlight the signaling mechanisms that could modulate synaptic plasticity and cerebellar learning. Moreover, we were able to identify new putative cGKI substrates that can shed more light on the cGMP–cGKI signaling pathways in the cerebellum.

Acknowledgments—Shabaz Mohammed, Teck Yew Low, and Harm Post are acknowledged for technical assistance. We thank Dr. Sergei Rybalkin and Dr. Joe Beavo for providing the anti-PDE5 antibody used for immunofluorescence staining of frozen sections.

* This work was in part supported by the PRIME-XS project (Grant No. 262067), funded by the European Union Seventh Framework Program. The Netherlands Proteomics Centre, embedded in The Netherlands Genomics Initiative, is acknowledged for funding.

[5] This article contains supplemental material.

† To whom correspondence should be addressed: Albert J. R. Heck, E-mail: aj.r.heck@uu.nl; Arjen Scholten, Tel.: 31-302535871, Fax: 31-302536919, E-mail: a.scholten@uu.nl.

**REFERENCES**

1. Geiger, T., Wehner, A., Schaab, C., Cox, J., and Mann, M. (2012) Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. *Mol. Cell. Proteomics* 11, M111.014050

2. Munoz, J., Low, T. Y., Kok, Y. J., Chin, A., Frese, C. K., Ding, V., Choo, A., and Heck, A. J. (2011) The quantitative proteomes of human-induced pluripotent stem cells and embryonic stem cells. *Mol. Syst. Biol.* 7, 550

3. Nagaraj, N., Kulak, N. A., Cox, J., Neuhauser, N., Mayr, K., Hoening, O., Vorn, O., and Mann, M. (2012) System-wide perturbation analysis with nearly complete coverage of the yeast proteome by single-shot ultra HPLC runs on a bench top Orbitrap. *Mol. Cell. Proteomics* 11, M111.013722

4. Krislinger, T., Cox, B., Kannan, A., Chung, C., Hu, P., Ignatzenko, A., Scott, M. S., Gramolini, A. O., Morris, Q., Hallett, M. T., Rossant, J., Hughes, T. R., Frey, B., and Emili, A. (2006) Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. *Cell* 125, 173–186

5. Huttlin, E. L., Jedrychowski, M. P., Elias, J. E., Goswami, T., Rad, R., Beausoleil, S. A., Villen, J., Haas, W., Sowa, M. E., and Gygi, S. P. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. *Cell* 143, 1174–1189

6. Aya, T. T., Scholten, A., Taoufas, N., Varro, A., Van Veen, T. A., Vos, M. A., and Heck, A. J. (2010) Proteome-wide protein concentrations in the human heart. *Mol. Biosyst.* 6, 1917–1927

7. Geiger, T., Velic, A., Macek, B., Lundberg, E., Kampf, C., Nagaraj, N., Uhlen, M., Cox, J., and Mann, M. (2013) Initial quantitative proteomic map of 28 mouse tissues using the SILAC mouse. *Mol. Cell. Proteomics* 12, 1708–1722

8. de Graaf, E. L., Vermeij, W. P., de Waard, M. C., Rijksen, G., van der Pluim, I., Hoogenraad, C. C., Hoeijmakers, J. H., Altealaa, A. F., and Heck, A. J. (2013) Spatio-temporal analysis of molecular determinants of neuronal degeneration in the aging mouse cerebellum. *Mol. Cell. Proteomics* 12, 1350–1362

9. Jing, L., Parker, C. E., Soo, D., Hines, M. W., Dicheva, N., Yu, Y., Schwinn, D., Ginsburg, G. S., and Chen, X. (2011) Discovery of biomarker candidates for coronary artery disease from an APOE-knock out mouse model using iTRAQ-based multiplex quantitative proteomics. *Proteins* 11, 2763–2776

10. Hilger, M., Bonaldi, T., Gnad, F., and Mann, M. (2009) Systems-wide analysis of a phosphatase knock-down by quantitative proteomics and phosphoproteomics. *Mol. Cell. Proteomics* 8, 1908–1920

11. Lundby, A., Andersen, M. N., Steffensen, A. B., Horn, H., Kelstrup, C. D., Francavilla, C., Jensen, L. J., Schmitt, N., Thomsen, M. B., and Olsen, J. V. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of beta-adrenergic receptor signaling. *Sci. Signal.* 6, rs11

12. Scholten, A., Preisinger, C., Corradini, E., Bourgonje, V. J., Hennrich, M. L., van Veen, T. A., Swaminathan, P. D., Joiner, M. L., Vos, M. A., Anderson, M. E., and Heck, A. J. (2013) Phosphoproteomics study based on in vivo inhibition reveals sites of calmodulin-dependent protein kinase II regulation in the heart. *J. Am. Heart Assoc.* 2, e000318

13. Hogg, D. M., Richardson, B. M., Foster, M. W., Everhart, A., Thompson, J. W., Moseley, M. A., and Colton, C. (2013) Longitudinal study of differential protein expression in an Alzheimer’s mouse model lacking inducible nitric oxide synthase. *J. Proteome Res.* 12, pp 4462–4477

14. Kleppisch, T., and Feil, R. (2009) cGMP signalling in the mammalian brain: role in synaptic plasticity and behaviour. *Handb. Exp. Pharmacol.* 191, 549–579

15. Francis, S. H., Busch, J. L., Corbin, J. D., and Sibley, D. (2010) cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. *Pharmacol. Rev.* 62, 525–563

16. Lohmann, S. M., Vaandrager, A. B., Smolenski, A., Walter, U., and De Jonge, H. R. (1997) Distinct and specific functions of cGMP-dependent protein kinases. *Trends Biochem. Sci.* 22, 307–312

17. Wernet, W., Flockerzi, V., and Hofmann, F. (1989) The cDNA of the two isoforms of bovine cGMP-dependent protein kinase. *FEBS Lett.* 251, 191–196

18. Kleppisch, T., Wolfsgruber, W., Feil, S., Altmann, R., Wotjak, C. T., Goebels, S., Nave, K. A., Hofmann, F., and Feil, R. (2003) Hippocampal cGMP-dependent protein kinase I supports an age- and protein synthesis-dependent component of long-term potentiation but is not essential for spatial reference and contextual memory. *J. Neurosci.* 23, 6005–6012

19. Ito, M. (2001) Cerebellar long-term depression: characterization, signal transduction, and functional roles. *Physiol. Rev.* 81, 1143–1185

20. Hofmann, F., and Sold, G. (1972) A protein kinase activity from rat cerebellum stimulated by guanosine-3′-5′-monophosphate. *Biochem. Biophys. Res. Commun.* 49, 1100–1107

21. Lohmann, S. M., Walter, U., Miller, P. E., Greengard, P., and De Camilli, P. (1981) Immunohistochemical localization of cyclic GMP-dependent pro-
tein kinase in mammalian brain. Proc. Natl. Acad. Sci. U.S.A. 78, 653–657
22. Hartell, N. A. (1994) cGMP acts within cerebellar Purkinje cells to produce long term depression via mechanisms involving PKC and PKG. Neuronport 5, 833–836
23. Feil, R., Hartmann, J., Luo, C., Wolfgunder, W., Schilling, K., Feil, S., Barski, J. J., Meyer, M., Konnerth, A., De Zeeuw, C. I., and Hofmann, F. (2003) Impairment of LTD and cerebellar learning by Purkinje cell-specific ablution of cGMP-dependent protein kinase I. J. Cell Biol. 163, 295–302
24. Wegener, J. W., Nawrath, H., Wolfgunder, W., Kuhbandner, S., Werner, C., Hofmann, F., and Feil, R. (2002) cGMP-dependent protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium. Circ. Res. 90, 18–20
25. Boersma, P. J., Rajmakers, R., Lemeer, S., Mohammed, S., and Heck, A. J. (2009) Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat. Protoc. 4, 484–494
26. Gautier, S., Helbig, A. O., Slipper, M., Kriegsveld, J., Heck, A. J., and Mohammed, S. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal. Chem. 81, 4489–4501
27. Zhou, H., Ye, M., Dong, J., Corradini, E., Cristobal, A., Heck, A. J., Zou, H., and Mohammed, S. (2013) Robust phosphoprotein enrichment using monodisperse microsphere-based immobilized titanium (IV) ion affinity chromatography. Nat. Protoc. 8, 461–480
28. Frese, C. K., Aitelaar, A. F., Henrich, M. L., Notting, D., Zeller, M., Griepe, Raming, J., Heck, A. J., and Mohammed, S. (2011) Improved peptide identification by targeted fragmentation using CID, HCD and ETD on an LTO-Orbitrap Velos. J. Proteome Res. 10, 2377–2388
29. Kovach, D., Cappadona, S., Rajmakers, R., Mohammed, S., Scholten, A., and Heck, A. J. (2012) Applications of stable isotope dimethyl labeling in quantitative proteomics. Anal. Bioanal. Chem. 404, 991–1009
30. Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372
31. Taus, T., Kocher, T., Pichler, P., Paschke, C., Henrich, C., and Mechtler, K. (2011) Universal and confident phosphorylation site localization using phosphoRS. J. Proteome Res. 10, 5354–5362
32. Szklarczyk, D., Franceschini, A., Kuhn, M., Simonovic, M., Roth, A., Minguez, P., Doerks, T., Stark, M., Muller, J., Bork, P., Jensen, L. J., and von Mering, C. (2011) The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39, D561–D568
33. Cline, M. S., Smoot, M., Cerami, E., Kuchinsky, A., Landys, N., Workman, C., Christmas, R., Avila-Campilo, I., Creech, M., Gross, B., Hanspers, K., Isserlin, R., Kelley, R., Killcoyne, S., Lotia, S., Maere, S., Morris, J., Ono, K., Pavlovic, V., Pico, A. R., Podsypanina, K., Pico, A. R., Vailaya, A., Wang, P. L., Adler, A., Conklin, B. R., Krombach, F., Ruth, P., Fassler, R., Korth, M., and Tachibana, H. (2013) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal. Chem. 81, 4489–4501
34. Hornbeck, P. V., Kornhauser, J. M., Tkachev, S., Chen, J., and Yu, A. (2005) Phosphorylation of phosphoprotein enriched in astrocytes (PEA-15) regulates extracellular signal-regulated kinase-dependent transcription and cell proliferation. Mol. Biol. Cell 16, 3552–3561
35. Thomson, T. M., Pedraza-Alva, G., Deng, B., Wood, C. D., Aronshtam, A., Clements, J. L., Sabio, G., Davis, R. J., Matthews, D. E., Doble, B., and Rincon, M. (2008) Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. J. Biol. Chem. 283, 2667–2670
36. Collinge-Ridge, G. L., Peineau, S., Howland, J. G., and Wang, Y. T. (2010) Long-term depression in the CNS. Nat. Rev. Neurosci. 11, 459–473
37. Stark, C., Breitkreutz, B. J., Reguly, T., Boucher, L., Breitkreutz, A., and Tyers, M. (2006) BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 34, D535–D539
38. Tong, T. S., Tu, H., Chan, E. Y., Maximov, A., Wang, Z., Wellington, C. L., Hayden, M. R., and Bezprozvanny, I. (2003) Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol(1,4,5)trisphosphate receptor type 1. Neuron 39, 227–239
39. Hofmann, F., Feil, R., Kleppisch, T., and Schlossmann, J. (2006) Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol. Rev. 86, 1–23
40. Sausbier, M., Schubert, R., Volgt, V., Hinne, C., Pfeifer, A., Korth, M., Kleppisch, T., Ruth, P., and Hofmann, F. (2000) Mechanisms of NO/cGMP-dependent vasorelaxation. Circ. Res. 87, 825–830
41. Massberg, S., Sausbier, M., Platt, B., Bauer, M., Pfeifer, A., Siess, W., Fassler, R., Roth, P., Krombach, F., and Hofmann, F. (1999) Increased adhesion and aggregation of platelets lacking cyclic guanosine 3’,5’-monophosphate kinase I. J. Exp. Med. 189, 1255–1264
42. Kumazoe, M., Sugihara, K., Tsukamoto, S., Huang, Y., Tsurudome, Y., Suzuki, T., Ueda, N., Ueda, N., Yamashita, S., Kim, Y., Yamada, K., and Tachibana, H. (2013) 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. J. Clin. Invest. 123, 787–799
43. Atken, A., Bilham, T., Cohen, P., Aswad, D., and Greengard, P. (1981) A specific substrate from rabbit cerebellum for guanosine-3’,5’-monophosphate-dependent protein kinase. III. Amino acid sequences at the two phosphorylation sites. J. Biol. Chem. 256, 3501–3506